{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"16"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","groups":[{"description":"V941(mRNA-5671/V941) 1 mg administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles","id":"OG000","title":"Part 1: V941 Monotherapy"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles","id":"OG001","title":"Part 1: V941 + Pembrolizumab"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG002","title":"Part 2: Expansion Cohort 1 Non-small Cell Lung Cancer (V941 + Pembrolizumab)"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG003","title":"Part 2: Expansion Cohort 2 Colorectal Cancer (V941 + Pembrolizumab)"},{"description":"V941(mRNA-5671/V941) 1 mg administered IM Q3W for 9 3-week cycles and pembrolizumab 200 mg, IV for 35 3-week cycles","id":"OG004","title":"Part 2: Expansion Cohort 3 Pancreatic Adenocarcinoma (V941 + Pembrolizumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least 1 dose of study treatment. For AEs which occurred during Part 1 prior to switch-over, the information is in the Part 1: V941 Monotherapy column. For AEs which occurred during Part 1 subsequent to switch-over, the information is in the Part 1: V941 + Pembrolizumab column.","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months","title":"Number of Participants Who Experienced an Adverse Event (AE)","type":"PRIMARY","unitOfMeasure":"Participants"}